Reported about 8 hours ago
Novo Nordisk's weight loss medications, Ozempic and Wegovy, will be included in the Medicare price negotiations set for 2027, alongside 13 other drugs. This comes after previous negotiations resulted in an average 22% price reduction under the Inflation Reduction Act. With Medicare spending $41 billion annually on these drugs, the financial impact on healthcare costs, particularly for obesity treatments, could be significant, while uncertainties persist about potential regulatory changes under a new Trump administration.
Source: YAHOO